The white paper describes MEG technology, its current clinical and research use, illustrates the comparison of MEG to EEG and importantly demonstrates how MEG can improve and accelerate the development of CNS drugs.

“There is a critical need for better tools to ascertain brain function in drug development, as well as novel biomarkers that identify neurological drug and disease signatures,” said Michael Gold, Vice President, GlaxoSmithKline.

Read more about how this novel application of MEG can accelerate drug development, reduce costs and improve CNS drug innovation by measuring neurological drug effects and real-time brain function throughout key phases of the drug development process.

Enter your name and email below to immediately access the white paper.

Name:
Email:
Please contact me to discuss the use of MEG in clinical trials.